---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113576"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:43:11.185007+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q3 net loss $49.9M; FDA aligns on BT8009 Phase 2/3 trial for bladder cancer

## Summary
- Net loss $49.9M ($1.26/share) vs $28.3M ($0.96/share) in Q3 2022; R&D expenses rose to $39.9M.
- Cash $572.1M as of Sep 30, 2023, up from $339.2M at Dec 31, 2022, including $215.1M net from July offering.
- FDA aligned on Phase 2/3 registrational trial (Duravelo-2) for BT8009 in metastatic bladder cancer; starts Q1 2024.
- BT8009 selected for FDA's CMC Development and Readiness Pilot (CDRP) program to expedite manufacturing.
- Company plans R&D Day on Dec 14, 2023, to provide updates on BT8009, BT5528, and BT7480.

## SEC filing metadata
- accession: 0001104659-23-113576
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/0001104659-23-113576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/tm2329595d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113576
- JSON: https://secwatch.observer/filing/0001104659-23-113576.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113576.txt

## Key facts
- Earnings Releases
  BICYCLE THERAPEUTICS PLC reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended September 30, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/0001104659-23-113576-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.